Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat
February 21, 2023 08:00 ET
|
CinCor Pharma Inc
WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor” or the “Company”) announced today completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration...
CinCor Pharma to be Acquired by AstraZeneca
January 09, 2023 02:05 ET
|
CinCor Pharma Inc
WALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has...
Correcting and Replacing: CinCor Reports Third Quarter Financial Results and Provides Corporate Update
November 04, 2022 08:00 ET
|
CinCor Pharma Inc
WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. is re-issuing its earnings press release for the third quarter ended September 30, 2022, issued on November 3, 2022 at 8:00 am...
CinCor Reports Third Quarter Financial Results and Provides Corporate Update
November 03, 2022 08:00 ET
|
CinCor Pharma Inc
Positive topline Phase 2 BrigHtn data demonstrating clinically meaningful and statistically significant reduction in blood pressure with baxdrostat in treatment-resistant hypertension Late-breaking...
CinCor Pharma to Present at the Jefferies Healthcare Conference
May 31, 2022 16:05 ET
|
CinCor Pharma Inc
WALTHAM, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced participation at the Jefferies 2022 Healthcare Conference taking place June 8 - 10 in New York,...
CinCor Pharma to Present at Upcoming Investor Conferences
May 17, 2022 16:05 ET
|
CinCor Pharma Inc
WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that management will present at the H.C. Wainwright 2022 Global Investment Conference taking place...
CinCor Reports First Quarter Financial Results and Provides Corporate Update
May 10, 2022 08:00 ET
|
CinCor Pharma Inc
Topline data for baxdrostat (CIN-107) in BrigHtn Phase 2 trial for treatment-resistant hypertension (rHTN) expected in 2H 2022 Topline data for baxdrostat (CIN-107) in HALO Phase 2 trial for...
CinCor Pharma to Participate in Jefferies Biotech on the Bay Summit
April 19, 2022 08:30 ET
|
CinCor Pharma Inc
WALTHAM, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) today announced its participation in the Jefferies Biotech on the Bay Summit taking place April 26-27 in...
CinCor Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
March 22, 2022 08:19 ET
|
CinCor Pharma Inc
BrigHtn Phase 2 study with CIN-107 for Resistant Hypertension Enrollment Complete with Topline Results Expected in 2H 2022 Topline Data from HALO Phase 2 study with CIN-107 for Uncontrolled...
CinCor Pharma to be Added to Russell 2000® and Russell 3000® Indexes
March 17, 2022 08:00 ET
|
CinCor Pharma Inc
BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the...